AstraZeneca's COPD drug tozorakimab cuts exacerbations by roughly 30% in Phase III trials

AZN reported Phase III results for tozorakimab showing a meaningful reduction in COPD exacerbations, with the primary population of former smokers seeing a 29% reduction in moderate exacerbations and a 34% reduction in severe ones. Across the trial's subgroups the effect ranged from 23% to 43%, so the headline figure describes a specific population rather than a uniform result.

The regulatory position is further along than a first read of the headline suggests. The drug is not awaiting a filing decision: it is already under FDA priority review, with a decision expected in the first quarter of 2027. That compresses the timeline between this readout and a commercial answer considerably.

AstraZeneca has guided to peak annual sales above $5 billion for the asset. That is a peak-sales estimate for the drug, not a 2030 figure and not to be confused with the company's separate $80 billion total-revenue ambition for 2030. COPD is a large and poorly served market, and an anti-IL-33 mechanism would be a genuinely new option in it, which is the reason the peak number is as large as it is.

What to watch: the full subgroup data when presented in a peer-reviewed venue, whether the current-smoker population shows a comparable benefit, and the FDA decision in early 2027. Competitive positioning against existing biologics in COPD will be set by how the label reads, not by the topline percentage.

Related Stocks

• AZN